56. Ultomiris


Active ingredient: ravulizumab
Disease: paroxysmal nocturnal hemoglobinuria
Peak sales estimate: $5 billion by 2022 (for Soliris and Ultomiris combined)
Approved: Dec. 21
Company: Alexion

The scoop: Alexion is out with a new-and-improved version of lead drug Soliris, and it’s not only more effective and more convenient—it’s cheaper, too. The company priced Ultomiris at a 10% discount to Soliris, whose maintenance doses run about $508,000 in rare disease paroxysmal nocturnal hemoglobinuria. And if Ultomiris can grab some of Soliris’ other indications, that discount could grow to 30%, Leerink Partners analyst Geoffrey Porges says. Meanwhile, Alexion will be working to switch patients over to the newer drug, which is dosed every eight weeks; its predecessor requires maintenance doses every two weeks. — Carly Helfand

56. Ultomiris

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.